Why is Tak 700 not being used when trials showed such great results ?

[Farn]

Tak 700 SWOG 1216 overall survival 81 months is this correct.

Of it is why is it not being talked about used deployed more ?

Can anyone enlighten me ?

Thank you in advance

[Tall_Allen]

You seem to have misunderstood. TAK 700 failed to show that it extended survival any better than a placebo. It failed before or after docetaxel.

ncbi.nlm.nih.gov/labs/pmc/a...

thelancet.com/journals/lano...

[Farn in reply to Tall_Allen]

cancertherapyadvisor.com/ho...

Hi am I misinterpreting this report the figure 81 months jumps off the page but have I got excited about a different type of prostate cancer ?

[Tall_Allen in reply to Farn]

There was no survival benefit. BOTH the treatment and control group had higher-than-expected survival. That often happens in clinical trials because all participating patients get such excellent medical attention.

[BruceSF in reply to Farn]

The 81 months median OS with TAK-700 was a very pleasant surprise, and it apparently means that the new treatments available at later stages (CRPC) are adding a couple of years to survival in general.

The 81 months median OS was almost statistically superior to the 70 months OS for the casodex control arm, which was also much larger than expected. The study author says “Obviously, not surprising, the SWOG 1216 trial has the highest overall survival of the control arm ever reported, ever, in the history of prostate cancer medicine.” He also says “SWOG 1216 has the highest number of patients who received a subsequent life-prolonging post-protocol therapy.” He concludes “it speaks about the access of these life-prolonging therapies approved in castrate-resistant prostate cancer setting to our patients in SWOG 1216.”

(The quotes are from an interview with the principal investigator on the study, Neeraj Agarwal at urotoday.com/categories-med... )

[LearnAll]

Ask LULU...I think he still takes Tak700.

[Hidden in reply to LearnAll]

I’m the only one here!

[BruceSF]

Tak-700 is a cyp-17a inhibitor, just like abiraterone (cyp-17a is an enzyme the body needs to make testosterone), so they are similar. In fact, the long term median Os for abiraterone from the stampede trial was 6.6 years, which is 79.2 months, which is similar to Tak-700’s 81 months, so a patient should get similar results with either drug.

[Farn in reply to BruceSF]

Thank you for this

[maley2711]

do we know he would not have had good luck without it?

[Hidden in reply to maley2711]

The shadow knows . I felt it gave me an untested edge! It gave Hope . ✌️

[maley2711 in reply to Hidden]

Hope is GOOD!!!

[btca]

A quick search found this informative info; 'orteronel' is the base name of Tak 700. This site gives a synopsis of the trial(s) and explains why the stage 3 trials were canceled.

[j-o-h-n]

Where's LuLu when we need him.... Probably taking a de-stuttering course since his real UserId is Lu.......

Good Luck, Good Health and Good Humor.

j-o-h-n Monday 01/31/2022 6:36 PM EST

[Hidden in reply to j-o-h-n]

Hoo -who ? Me . Im just a gigolo, life goes on without Me!

[Hidden]

Thanks Nal .

[Hidden]

Dam! I’m at 80 months now!😳

[Hidden]

Amen brother🙏

[Farn]

Thank you for the insight

[Hidden in reply to Farn]

Best of luck Sir!